Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?

At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from , Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of ...

But the story could change for Summit in the not-too-distant future. Summit expects to report top-line results in mid-2025 from a late-stage clinical study evaluating ivonescimab as a second-line ...

Those include Summit Therapeutics and Akeso's PD-1xVEGF bispecific antibody ivonescimab, which outperformed Keytruda in a lung cancer study and has also shown promise in previously- untreated ...